Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. Knight said the repayment was funded through strong cash flow generated by its operations in Canada and Latin America.
The early repayment signals financial strength and prudent capital management. By retiring the debt ahead of schedule, Knight reduces interest expenses and strengthens its balance sheet. The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions, supporting the company’s ongoing growth strategy across its pan-American pharmaceutical business. For full details, see the press release at https://ibn.fm/8eluB.
The Paladin acquisition, completed in June 2025, expanded Knight’s portfolio of specialty pharmaceutical products in Canada and Latin America. Paladin is known for its neurology, psychiatry, and pain management products. The decision to use internal cash flows for repayment rather than refinancing demonstrates confidence in the company's operational performance and market position.
Knight Therapeutics, headquartered in Montreal, Canada, focuses on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company’s shares trade on the TSX under the symbol GUD. More information is available at https://www.knighttx.com.
The repayment is particularly noteworthy amid a high-interest-rate environment, as many companies struggle with debt servicing. Knight’s ability to generate sufficient cash flow to repay $60 million while continuing to invest in growth initiatives underscores the resilience of its business model. The maintained borrowing capacity of up to US$200 million provides flexibility to pursue additional acquisitions or investments without immediate financing constraints.
This development may positively influence investor sentiment by highlighting Knight’s disciplined financial management and strong operational cash generation. It also reduces exposure to variable interest rates, lowering financial risk. The news comes as the company continues to expand its footprint in Latin America, a region with growing demand for specialty pharmaceuticals.
Knight Therapeutics’ proactive debt repayment aligns with its strategy of building a sustainable pan-American pharmaceutical platform. The company has a track record of integrating acquisitions successfully while maintaining healthy margins. The Paladin acquisition is expected to contribute to earnings growth in the coming quarters, supported by a robust product pipeline and established commercial infrastructure.
